India's No.1 Weekly For The Pharmaceutical Industry
About us || Feedback|| Advertising || Subscribe || Archives / Search 

 

Issue dated - 14th April 2005

Home > Corporate > Story Printer Friendly Page|  Email this page

Strides Arcolab issues USD 40 million foreign currency convertible bonds

EPP News Bureau - Mumbai

Strides Arcolab Limited, a leading Indian developer and manufacturer of pharmaceuticals announced an agreement to privately place an offering of USD 40 million foreign currency convertible bonds (FCCBs) with Deutsche Bank acting as the sole underwriter subject to shareholder approvals.

According to a press release, the bonds of five year tenure have an issue price of 100 per cent of par carrying 0.5 per cent coupon bonds can be redeemed at a premium to par to yield 6.8 per cent per annum. The bonds convert into ordinary shares of Strides Arcolab at a conversion price of Rs 358.70. The issuance of the bonds is subject to approval by the EGM on 12 April, 2005 and the bonds are expected to be listed on the Singapore Stock Exchange.

Strides listed on the Indian National Stock Exchange and the Bombay Stock Exchange (BSE) has a global presence in more than 50 countries. The company has factories in India, Brazil, Mexico and USA.

INSIDE PHARMA
MARKETPLACE
EDIT
OPED
HEALTH NEWS
HAPPENINGS
IN THE NEWS
CORPORATE
NUTRACEUTICALS
TECHNOLOGY TRENDZ
PRODUCTS
MEDICINAL PLANTS
CONVERSATION
ARCHIVES
SUBSCRIBE
CUSTOMER SERVICE
CONTACT US
ADVERTISE
ABOUT US

 Network Sites

  Express Computer

  IT People
  Network Magazine
  Business Traveller
  Hotelier & Caterer
  Travel & Tourism
  Healthcare Mgmt.
  Express Textile
 Group Sites
  ExpressIndia
  Indian Express
  Financial Express
<Top of page>
ABOUT US FEEDBACK ADVERTISE SUBSCRIBE ARCHIVES
 

© Copyright 2001: Indian Express Newspapers (Mumbai) Limited (Mumbai, India). All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of the Indian Express Newspapers (Mumbai) Limited. Site managed by BPD.